FindTrial
Sign In

ABP 654

DRUG2 trials

Sponsors

Amgen

Conditions

Plaque PsoriasisPsoriasis

Phase 3

A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
CompletedNCT04607980
AmgenPlaque Psoriasis
Start: 2020-11-11End: 2022-06-03Updated: 2024-12-12
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
CompletedNCT04761627
AmgenPsoriasis
Start: 2021-03-24End: 2023-02-28Updated: 2024-01-11

Related Papers

Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks
British Journal of Dermatology2024-10-239 citations